化学
HDAC6型
苯甲酰胺
神经保护
组蛋白脱乙酰基酶
药理学
异羟肟酸
阿尔茨海默病
IC50型
组蛋白脱乙酰酶抑制剂
磷酸化
生物化学
组蛋白
疾病
立体化学
内科学
体外
基因
医学
作者
Hsueh‐Yun Lee,Sheng-Jun Fan,Fang-I Huang,Hsin-Yi Chao,Kai‐Cheng Hsu,Tony Eight Lin,Teng‐Kuang Yeh,Mei-Jung Lai,Yu-Hsuan Li,Hsiang-Ling Huang,Chia‐Ron Yang,Jing‐Ping Liou
标识
DOI:10.1021/acs.jmedchem.8b00151
摘要
This paper reports the development of a series of 5-aroylindolyl-substituted hydroxamic acids. N -Hydroxy-4-((5-(4-methoxybenzoyl)-1 H -indol-1-yl)methyl)benzamide ( 6 ) has potent inhibitory selectivity against histone deacetylase 6 (HDAC6) with an IC 50 value of 3.92 nM. It decreases not only the level of phosphorylation of tau proteins but also the aggregation of tau proteins. Compound 6 also shows neuroprotective activity by triggering ubiquitination. In animal models, compound 6 is able to ameliorate the impaired learning and memory, and it crosses the blood–brain barrier after oral administration. Compound 6 can be developed as a potential treatment for Alzheimer’s disease in the future.
科研通智能强力驱动
Strongly Powered by AbleSci AI